Ticker Details
Myriad Genetics, Inc. Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.
IPO Date:	October 6, 1995
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$399.89M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 1.92%
Avg Daily Range (30 D):	$0.16 | 2.81%
Avg Daily Range (90 D):	$0.16 | 2.51%

Institutional Daily Volume
Avg Daily Volume:	.93M
Avg Daily Volume (30 D):	.91M
Avg Daily Volume (90 D):	.82M

Trade Size
Avg Trade Size (Sh.):	133
Avg Trade Size (Sh.) (30 D):	71
Avg Trade Size (Sh.) (90 D):	67

Institutional Trades
Total Institutional Trades:	11,788
Avg Institutional Trade:	$1.85M
Avg Institutional Trade (30 D):	$1.03M
Avg Institutional Trade (90 D):	$1.29M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.47M
Avg Closing Trade (30 D):	$1.05M
Avg Closing Trade (90 D):	$1.28M
Avg Closing Volume:	110.1K

News

Feb 16, 2026 @ 9:15 PM Myriad Genetics to Release Fourth Quarter and Full... Source: Na

Feb 13, 2026 @ 3:00 PM Decoding Our DNA: The Human Impact Behind SNP Geno... Source: Towards Healthcare

Jan 30, 2026 @ 9:57 AM Esoteric Testing Research Report 2026 - Global $41... Source: Researchandmarkets.Com

Jan 16, 2026 @ 10:58 AM Global Pan-Genomic and Multi-Gene Panel Testing Ma... Source: Analystview Market Insights

Dec 30, 2025 @ 3:00 PM Reproductive Genetics Market Size to Reach USD 16.... Source: Coherent Market Insights

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-4.33	$-.29	$-3.57
Diluted EPS	$-4.33	$-.29	$-3.57
Revenue	$825.3M	$205.7M	$213.1M
Gross Profit	$580.7M	$143.8M	$151.8M
Net Income / Loss	$-400.5M	$-27.4M	$-330.5M
Operating Income / Loss	$-420.5M	$-23.3M	$-329.2M
Cost of Revenue	$244.6M	$61.9M	$61.3M
Net Cash Flow	$45M	$71.1M	$-17.3M
PE Ratio

Splits
Mar 26, 2009	2:1
Sep 12, 2000	2:1